title: Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.
authors.affiliation: Drop code 5024, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. emeadows@lilly.com
authors.forename: Eric S
authors.initials: ES
authors.lastname: Meadows
authors.forename: John
authors.initials: J
authors.lastname: Stock
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Johnston
mesh_terms: D019386:Alendronate / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000191:economics*; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000191:economics; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000191:economics* / Q000401:mortality; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000191:economics* / Q000401:mortality
chemical_list: D050071:Bone Density Conservation Agents; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D019386:Alendronate